S
Shattuck Labs
Shattuck Labs, Inc operates as a biotechnology company
About Shattuck Labs
Shattuck Labs is a biotechnology company specializing in the development of bi-functional fusion proteins through its proprietary Agonist Redirected Checkpoint (ARC) technology. The company focuses on creating advanced therapeutic solutions that target both clinically validated and emerging pathways. Shattuck Labs serves clients in the healthcare and pharmaceutical sectors, aiming to provide best-in-class and first-in-class therapies. The company operates in the biopharmaceutical market, leveraging its robust drug pipeline of over 300 fusion proteins to address unmet medical needs. Shattuck Labs generates revenue through the development, licensing, and commercialization of its proprietary therapies. The business model includes partnerships with other pharmaceutical companies and research institutions to advance its drug candidates through clinical trials and regulatory approvals. Keywords: biotechnology, fusion proteins, ARC technology, therapeutic solutions, healthcare, pharmaceutical, drug pipeline, licensing, commercialization, clinical trials.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2016
- Headquarters
- Austin, United States
- Listing
- IPO 2020
- Employees
- 59
- Open positions
- 1
- Dealroom signal
- 79.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Latest news
Press, funding announcements and product moves mentioning Shattuck Labs.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2026 | $55M | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VCOther financing | Aug 2025 | $103M | — | Adage Capital · OrbiMed · Coastland Capital · Presight Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $1M | 0% | −$61M | -6082% |
| 2025 | $1M | -82.5% | −$48M | -4782% |
| 2024 | $5.7M | +245.3% | −$77M | -1341.3% |
| 2023 | $1.7M | +154.1% | −$88M | -5305.7% |
| 2022 | $652K | -97.8% | −$103M | -15848% |
| 2021 | $30M | +202.2% | −$44M | -146.2% |
| 2020 | $9.9M | — | −$37M | -371.8% |
Growth signals
Latest recorded traffic for Shattuck Labs is 6K monthly website visits, up 33.3% over the last three months. Shattuck Labs's team declined 28% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Redmile Group
Fidelity Investments
Emerson Collective
PFM Health Sciences
Piper Sandler
Hatteras Venture Partners
Janus Henderson Investors
EcoR1 Capital
Avidity Partners
Other known investors6 additional known investors
Adage Capital- CCCoastland Capital
Glancy Binkow & Goldberg LLP- NCNEXTBio Capital
OrbiMed
Presight Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shattuck Labs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shattuck Labs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.